Takshveer Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Takshveer Singh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Angela R. Schneider
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
1 shared publication Anita A. Wong
Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
1 shared publication- Brittney N. V. Scott
Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Byron Michael Berenger
Provincial Laboratory for Public Health, Alberta Precision Laboratories
1 shared publication - Danielle Portnoy
Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Graham Tipples
Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
1 shared publication
Latest Publications
- Open Access
- 26 July 2021
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 70 (7) , 001372
Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19
Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of specimen collection. Gap statement. Clinical data on the performance of the ID NOW are limited, with many studies varying in their study design and/or having small sample size. Aim. In this study we aimed to determine the clinical performance of the ID NOW compared to conventional RT-PCR testing. Methodology. Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV-2 RT-PCR assay targeting the E gene. Results. In total, 133 individuals were included in the study; 129 samples were positive on either the ID NOW and/or RT-PCR. Assuming any positive result on either assay represents a true positive, positive per cent agreement (PPA) of the ID NOW compared to RT-PCR with 95 % confidence intervals was 89.1 % (82.0–94.1%) and 91.6 % (85.1–95.9%), respectively. When analysing individuals with symptom duration ≤7 days and who had the ID NOW performed within 1 h (n=62), ID NOW PPA increased to 98.2 %. Conclusion. Results from the ID NOW were reliable, especially when adhering to the manufacturer’s recommendations for testing.
- 26 July 2021
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 70 (7) , 001372
Open AccessAcceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19
Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of specimen collection. Gap statement. Clinical data on the performance of the ID NOW are limited, with many studies varying in their study design and/or having small sample size. Aim. In this study we aimed to determine the clinical performance of the ID NOW compared to conventional RT-PCR testing. Methodology. Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV-2 RT-PCR assay targeting the E gene. Results. In total, 133 individuals were included in the study; 129 samples were positive on either the ID NOW and/or RT-PCR. Assuming any positive result on either assay represents a true positive, positive per cent agreement (PPA) of the ID NOW compared to RT-PCR with 95 % confidence intervals was 89.1 % (82.0–94.1%) and 91.6 % (85.1–95.9%), respectively. When analysing individuals with symptom duration ≤7 days and who had the ID NOW performed within 1 h (n=62), ID NOW PPA increased to 98.2 %. Conclusion. Results from the ID NOW were reliable, especially when adhering to the manufacturer’s recommendations for testing.